Tacrolimus vs Cyclosporine for Anti-Rejection and Cardiac Side Effects

Introduction to Immunosuppression

The American Heart Association recommends switching from tacrolimus to cyclosporine as part of optimizing maintenance immunosuppression when managing antibody-mediated rejection with hemodynamic concerns 1, 2

Cyclosporine is more commonly associated with hypertension, hypercholesterolemia, dyslipidemia, hirsutism, and gingival hyperplasia, whereas tacrolimus is more frequently associated with diabetes mellitus, neurotoxicity, diarrhea, and alopecia 3
Both agents share similar degrees of nephrotoxicity, hyperkalemia, and general immunosuppression-related risks 3

Ensure adequate anti-rejection control before switching from tacrolimus to cyclosporine, and avoid conversion during active rejection episodes 1, 2
Optimize adjunctive immunosuppression by considering adding or maximizing mycophenolate mofetil (MMF) or sirolimus, which are potent B-cell inhibitors that allow lower calcineurin inhibitor doses 1
Target cyclosporine trough levels of 200-300 ng/mL initially, then 50-150 ng/mL for long-term maintenance 3
Monitor closely during transition with levels every 2-3 days initially, as both drugs have narrow therapeutic windows and significant interindividual pharmacokinetic variation 3

Continue therapeutic drug monitoring monthly once stable levels achieved, and monitor for cyclosporine-specific toxicities including lipid panels, blood pressure, and gingival health 3
Consider combination therapy with MMF or sirolimus to allow lower cyclosporine doses and preserve renal function 1, 3
Maintain a lower threshold for endomyocardial biopsy given the potentially higher rejection risk compared to tacrolimus, and be aware that rejection risk increases with the switch from tacrolimus to cyclosporine 3